April 10, 2021
Business News

Genmab’s stock surges after drug development deal with AbbView valued at up to nearly $4 billion – MarketWatch

Shares of Genmab A/S
rose 4.5% in premarket trading Wednesday, after the Denmark-based biotechnology company announced a collaboration agreement with AbbVie Inc.

Click here to view the original article.

Related Posts

You might also like ...

EIG ondertekent infrastructuurovereenkomst van $ 12,4 miljard met Aramco
Article feature image
China fines Alibaba record $2.75 billion for anti-monopoly violations – Reuters
Article feature image
AstraZeneca Vaccine and Blood Clots: What Is Known So Far – The New York Times